Ticker Details
AnaptysBio, Inc. AnaptysBio Inc is a biotechnology company. The company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.
IPO Date:	January 26, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.97B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.08 | 2.93%
Avg Daily Range (30 D):	$1.57 | 2.67%
Avg Daily Range (90 D):	$2.05 | 3.44%

Institutional Daily Volume
Avg Daily Volume:	.32M
Avg Daily Volume (30 D):	.46M
Avg Daily Volume (90 D):	.5M

Trade Size
Avg Trade Size (Sh.):	71
Avg Trade Size (Sh.) (30 D):	47
Avg Trade Size (Sh.) (90 D):	52

Institutional Trades
Total Institutional Trades:	3,418
Avg Institutional Trade:	$1.87M
Avg Institutional Trade (30 D):	$5.07M
Avg Institutional Trade (90 D):	$3.65M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.94M
Avg Closing Trade (30 D):	$7.38M
Avg Closing Trade (90 D):	$5.68M
Avg Closing Volume:	55.32K

News

Apr 24, 2026 @ 7:40 PM Delaware Chancery Court Rules in Favor of Anaptys ... Source: Na

Jan 8, 2026 @ 11:00 PM Anaptys Files Motion to Dismiss Tesaro’s Cl... Source: Na

Nov 21, 2025 @ 1:48 PM GSK Unit Tesaro Sues AnaptysBio, Threatening Key C... Source: Vandana Singh

Nov 21, 2025 @ 8:50 AM Anaptys Initiates Litigation Against Tesaro, a GSK... Source: Anaptysbio

Sep 29, 2025 @ 9:06 PM 12 Health Care Stocks Moving In Monday's After-Mar... Source: Benzinga Staff Writer

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.94	$-1.84	$1.7
Diluted EPS	$-.96	$-1.84	$1.7
Revenue	$232.39M	$25.56M	$108.25M
Gross Profit
Net Income / Loss	$-26.79M	$-52.88M	$49.61M
Operating Income / Loss	$40.8M	$-34.64M	$66.9M
Cost of Revenue
Net Cash Flow	$149.83M	$10.27M	$128.36M
PE Ratio